Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

How our clients use DrugPatentWatch

Generated: April 24, 2017

DrugPatentWatch Database Preview

AZOR Drug Profile

« Back to Dashboard

What is the patent landscape for Azor, and what generic alternatives are available?

Azor is a drug marketed by Daiichi Sankyo and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.

This drug has ninety-eight patent family members in twenty-seven countries.

The generic ingredient in AZOR is amlodipine besylate; olmesartan medoxomil. There are forty-nine drug master file entries for this compound. Seven suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the amlodipine besylate; olmesartan medoxomil profile page.

Summary for Tradename: AZOR

Suppliers / Packagers: see list3
Bulk Api Vendors: see list34
Clinical Trials: see list4
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:AZOR at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Daiichi Sankyo
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-001Sep 26, 2007ABRXYesNo5,616,599*PED► Subscribe ► Subscribe
Daiichi Sankyo
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-004Sep 26, 2007ABRXYesYes5,616,599*PED► Subscribe ► Subscribe
Daiichi Sankyo
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-002Sep 26, 2007ABRXYesNo5,616,599*PED► Subscribe ► Subscribe
Daiichi Sankyo
amlodipine besylate; olmesartan medoxomil
TABLET;ORAL022100-003Sep 26, 2007ABRXYesNo5,616,599*PED► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Find generic sources and suppliers
  • Predict branded drug patent expiration
  • Uncover prior art in abandoned patent applications and expired patents

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

How our clients use DrugPatentWatch

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus